Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp (NQ: LEXX )

3.201 +0.021 (+0.66%)
Streaming Delayed Price Updated: 9:39 AM EDT, May 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lexaria Bioscience Corp

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
21 22 Next >
Nicotine Surges as Smoking Sags
NetworkNewsWire Editorial Coverage New York, NY – May 24, 2022 – Seems like yesterday people were smoking cigarettes everywhere; many people still have memories of Grandpa puffing on his Camels. It... 
Via FinancialNewsMedia
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Aims to Deliver Safer Alternative for Nicotine Experience
Via CannabisNewsWire
Topics Death Intellectual Property
Exposures Death Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Aims to Deliver Safer Alternative for Nicotine Experience
Via Investor Brand Network
Topics Death Intellectual Property
Exposures Death Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Devoting Research, Product Development to Make Drug Substances More Effective
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Influencing the Pharmaceutical Industry
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-Nicotine Pouch Performance to Be Compared to That of Leading Brands
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-Nicotine Pouch Performance to Be Compared to That of Leading Brands
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Readying Human Study to Compare Lexaria’s DehydraTECH-Nicotine Pouch Performance to that of Existing Leading Brands
Via CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Readying Human Study to Compare Lexaria’s DehydraTECH-Nicotine Pouch Performance to that of Existing Leading Brands
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands its Patent Portfolio With New Patent for Antiviral Drug Delivery with DehydraTECH
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Unlock Capabilities of Revolutionary DehydraTECH(TM) Platform
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Unlock Capabilities of Revolutionary DehydraTECH(TM) Platform
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Fourth Human Study for Reducing Hypertension, Reports Positive Outcome of Third Human Study’s Data
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Advancing DehydraTECH-Nicotine Research to Support Safer, More Effective Oral Alternative to Harmful Pulmonary Administration Practices
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Advancing DehydraTECH-Nicotine Research to Support Safer, More Effective Oral Alternative to Harmful Pulmonary Administration Practices
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures First-Ever Patent for DehydraTECH to Deliver Antiviral Drugs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures First-Ever Patent for DehydraTECH to Deliver Antiviral Drugs
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
- 25th patent grant is Lexaria's first-ever patent for the enhanced delivery of antivirals KELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences Its Most Comprehensive Study to Date
Via Investor Brand Network
Exposures Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences Its Most Comprehensive Study to Date
Via CannabisNewsWire
Exposures Product Safety
Lexaria (NASDAQ: LEXX) Advances Human Nicotine Study, Announces New Program with Altria
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Commences Multi-Week Human Clinical Hypertension Study
- HYPER-H21-4 will evaluate DehydraTECHTM-CBD for reducing blood pressure together with other potential clinical benefits - This study is designed to enhance Lexaria's probabilities of success with its... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Advances its Human Nicotine Study and Announces New Nicotine Formulation Creation and Evaluation Program with Altria
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience (NASDAQ: LEXX) Announces Positive Results from Hypertension Study
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Results from Pulmonary Hypertension Clinical Study
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Results from Pulmonary Hypertension Clinical Study
Via Investor Brand Network
Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Bioscience (NASDAQ: LEXX) Issues Update on Human Nicotine Study
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1
Via CannabisNewsWire
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.